F13B (Coagulation factor XIII B chain) variants and mutations
F13B (also known as Coagulation factor XIII B chain) is a human protein-coding gene encoding a coagulation factor XIII B chain protein. It circulates bound to the catalytic factor XIII A subunits and stabilizes them in plasma before clotting activation. Biallelic deficiency lowers circulating factor XIII and can cause a bleeding tendency, generally milder than complete F13A1 deficiency. This analysis covers 1,110 F13B variants and mutations. Of these, 71% have computational variant effect predictions. Disease context includes congenital factor XIII deficiency, age-related macular degeneration, and macular degeneration. Example F13B variants include R2K, L3F, and K4E.
Variant analysis overview
- Gene: F13B
- Protein: Coagulation factor XIII B chain
- UniProt accession: P05160
- Organism: Homo sapiens
- Variants analyzed: 1110
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 887 unspecified-consequence records; 1 stop retained variant; 80 synonymous variants; 4 in-frame deletions; 20 frameshift variants; 113 missense variants; 6 stop-gained variants; 1 splice-region variants; 2 substitution
- Prediction scores: 791 variants have prediction scores (71% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: congenital factor XIII deficiency, age-related macular degeneration, macular degeneration, coagulation protein disease, factor XIII deficiency, cholesteatoma, hereditary disease, psoriasis, thrombotic disease, retinal disorder, stroke disorder, Stroke.
Protein structure and variant hotspots
- Protein features: 10 domains; 2 post-translational modification sites.
- Structural context: 1,036 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable F13B variants
Examples include R2K, L3F, K4E, T7I, I9F, I11T, L12*, L12S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- R2K (p.Arg2Lys), Ensembl rs2125078285, REVEL 0.09, CADD 1.13, Uncertain significance, not provided
- L3F (p.Leu3Phe), ExAC rs777879309, gnomAD rs777879309
- K4E (p.Lys4Glu), ExAC rs772099185, gnomAD rs772099185, REVEL 0.04, CADD 15.30
- T7I (p.Thr7Ile), ExAC rs764028506, TOPMed rs764028506, gnomAD rs764028506, REVEL 0.07, CADD 3.24
- I9F (p.Ile9Phe), TOPMed rs1656090778, gnomAD rs1656090778, REVEL 0.06, CADD 13.30
- I11T (p.Ile11Thr), ExAC rs755472323, REVEL 0.12, CADD 21.20
- L12* (p.Leu12Ter), gnomAD rs1169927860
- L12S (p.Leu12Ser), gnomAD rs1169927860, REVEL 0.13, CADD 16.00
- I13V (p.Ile13Val), NCI-TCGA Cosmic COSV1008, REVEL 0.04, CADD 2.34, Variant assessed as somatic; moderate impact.
- S15P (p.Ser15Pro), TOPMed rs1656089318
- G16* (p.Gly16Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E17* (p.Glu17Ter), NCI-TCGA Cosmic COSV6637, CADD 33.00, Variant assessed as somatic; high impact.
- L18V (p.Leu18Val), gnomAD rs1183401714, REVEL 0.05, CADD 19.20
- Y19C (p.Tyr19Cys), ExAC rs780445814, TOPMed rs780445814, gnomAD rs780445814, REVEL 0.13, CADD 7.70
- A20T (p.Ala20Thr), ExAC rs756460140, TOPMed rs756460140, gnomAD rs756460140, REVEL 0.13, CADD 24.20
- A20V (p.Ala20Val), TOPMed rs1656088540, REVEL 0.14, CADD 23.70
- E22D (p.Glu22Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E22K (p.Glu22Lys), TOPMed rs1194658526, gnomAD rs1194658526, REVEL 0.04, CADD 33.00
- K23Q (p.Lys23Gln), TOPMed rs1047178726, gnomAD rs1047178726, REVEL 0.08, CADD 25.10
- P24L (p.Pro24Leu), NCI-TCGA Cosmic COSV6637, REVEL 0.13, CADD 9.14, Variant assessed as somatic; moderate impact.
- P24S (p.Pro24Ser), ExAC rs756436929, TOPMed rs756436929, gnomAD rs756436929, REVEL 0.11, CADD 8.60
- P24T (p.Pro24Thr), ExAC rs756436929, TOPMed rs756436929, gnomAD rs756436929, REVEL 0.08, CADD 8.19, Uncertain significance, not provided
- C25R (p.Cys25Arg), rs1232302447, UniProt VAR 074563, TOPMed rs1232302447, gnomAD rs1232302447, REVEL 0.92, CADD 27.10, Pathogenic, in FA13BD
- G26R (p.Gly26Arg), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- P28S (p.Pro28Ser), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- H29L (p.His29Leu), rs1655925611, ClinGen CA344008961, ClinVar RCV003388291, TOPMed rs1655925611, REVEL 0.07, CADD 0.66, Uncertain significance, Factor XIII, b subunit, deficiency of
- H29Q (p.His29Gln), Ensembl rs900935516, REVEL 0.06, CADD 9.65
- H29Y (p.His29Tyr), gnomAD rs1406785192, REVEL 0.13, CADD 4.89
- V30A (p.Val30Ala), Ensembl rs1571571104
- V30M (p.Val30Met), gnomAD rs1382286356, REVEL 0.27, CADD 22.70
- E31A (p.Glu31Ala), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; moderate impact.
- E31K (p.Glu31Lys), ExAC rs781729626, gnomAD rs781729626, REVEL 0.23, CADD 25.10, Uncertain significance, Inborn genetic diseases
- N32Y (p.Asn32Tyr), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- G33E (p.Gly33Glu), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- G33R (p.Gly33Arg), gnomAD rs1184878385, REVEL 0.57, CADD 26.70
- G33V (p.Gly33Val), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- R34I (p.Arg34Ile), rs756961824, NCI-TCGA Cosmic COSV6637, ExAC rs756961824, gnomAD rs756961824, REVEL 0.34, CADD 24.40, Variant assessed as somatic; moderate impact.
- I35S (p.Ile35Ser), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- I35T (p.Ile35Thr), gnomAD rs1459223017, REVEL 0.37, CADD 25.90
- A36V (p.Ala36Val), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; moderate impact.
- Y38C (p.Tyr38Cys), gnomAD rs1199651158, REVEL 0.39, CADD 24.60
- Y38H (p.Tyr38His), ExAC rs751293222, gnomAD rs751293222
- Y39H (p.Tyr39His), NCI-TCGA Cosmic COSV6637, Ensembl rs1655923872, Variant assessed as somatic; moderate impact.
- Y40C (p.Tyr40Cys), rs1453580885, NCI-TCGA Cosmic COSV6637, gnomAD rs1453580885, REVEL 0.32, CADD 27.20, Variant assessed as somatic; moderate impact.
- F42C (p.Phe42Cys), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- F42L (p.Phe42Leu), Ensembl rs112953172
- S44I (p.Ser44Ile), rs762573806, ClinGen CA1308654, ClinVar RCV002745058, ExAC rs762573806, REVEL 0.12, CADD 19.30, Uncertain significance, Inborn genetic diseases
- S44R (p.Ser44Arg), ExAC rs752638957, TOPMed rs752638957, gnomAD rs752638957, REVEL 0.06, CADD 4.58, Uncertain significance, Inborn genetic diseases
- F45L (p.Phe45Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y46* (p.Tyr46Ter), ESP rs369407891, ExAC rs369407891, TOPMed rs369407891, gnomAD rs369407891, CADD 35.00
- M49I (p.Met49Ile), ExAC rs776286731, TOPMed rs776286731, gnomAD rs776286731, REVEL 0.31, CADD 24.70
- M49V (p.Met49Val), rs6002, UniProt VAR 013930, 1000Genomes rs6002, ExAC rs6002, REVEL 0.23, CADD 25.20
- S50I (p.Ser50Ile), gnomAD rs1274967585, REVEL 0.19, CADD 14.00
- S50N (p.Ser50Asn), rs1274967585, NCI-TCGA Cosmic COSV6637, gnomAD rs1274967585, REVEL 0.09, CADD 1.99, Variant assessed as somatic; moderate impact.
- I51T (p.Ile51Thr), ExAC rs766202207, TOPMed rs766202207, gnomAD rs766202207, REVEL 0.14, CADD 14.00
- D52N (p.Asp52Asn), Ensembl rs867206988
- D52V (p.Asp52Val), TOPMed rs1655921937, REVEL 0.12, CADD 14.30
- K53E (p.Lys53Glu), 1000Genomes rs200113225, TOPMed rs200113225, gnomAD rs200113225, REVEL 0.12, CADD 5.12
- K53Q (p.Lys53Gln), 1000Genomes rs200113225, TOPMed rs200113225, gnomAD rs200113225, Likely benign, Inborn genetic diseases
- K53R (p.Lys53Arg), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- K54E (p.Lys54Glu), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; moderate impact.
- K54T (p.Lys54Thr), NCI-TCGA TCGA novel, TOPMed rs1655921674, Variant assessed as somatic; moderate impact.
- L55M (p.Leu55Met), 1000Genomes rs12752091, ExAC rs12752091
- L55S (p.Leu55Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S56* (p.Ser56Ter), Ensembl rs1655921180, CADD 33.00
- S56L (p.Ser56Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S56P (p.Ser56Pro), TOPMed rs1192579982
- C59W (p.Cys59Trp), ExAC rs774579966, gnomAD rs774579966, REVEL 0.81, CADD 24.30
- L60V (p.Leu60Val), TOPMed rs1478877084
- A61G (p.Ala61Gly), TOPMed rs1447128343, gnomAD rs1447128343, REVEL 0.20, CADD 25.00
- A61S (p.Ala61Ser), 1000Genomes rs200833921, ExAC rs200833921, REVEL 0.21, CADD 23.80
- A61V (p.Ala61Val), NCI-TCGA TCGA novel, TOPMed rs1447128343, gnomAD rs1447128343, REVEL 0.05, CADD 21.30, Variant assessed as somatic; moderate impact.
- G62A (p.Gly62Ala), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- G62R (p.Gly62Arg), gnomAD rs1246809495
- G62S (p.Gly62Ser), NCI-TCGA Cosmic COSV1008, REVEL 0.75, CADD 31.00, Variant assessed as somatic; moderate impact.
- Y63S (p.Tyr63Ser), TOPMed rs1655919724
- T64I (p.Thr64Ile), ExAC rs749334266, TOPMed rs749334266, gnomAD rs749334266, REVEL 0.39, CADD 24.30
- T65A (p.Thr65Ala), TOPMed rs1418533213
- E66K (p.Glu66Lys), TOPMed rs1208827662, gnomAD rs1208827662, REVEL 0.04, CADD 2.90
- S67G (p.Ser67Gly), gnomAD rs1468749902
- S67N (p.Ser67Asn), Ensembl rs12732168
- S67R (p.Ser67Arg), ExAC rs12752075, TOPMed rs12752075, gnomAD rs12752075
- Q70* (p.Gln70Ter), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; high impact.
- Q70P (p.Gln70Pro), ESP rs149369147, ExAC rs149369147, TOPMed rs149369147, gnomAD rs149369147, REVEL 0.29, CADD 22.60, Uncertain significance, Inborn genetic diseases
- E72A (p.Glu72Ala), TOPMed rs946949060
- E72G (p.Glu72Gly), TOPMed rs946949060, REVEL 0.09, CADD 0.02
- Q73K (p.Gln73Lys), ExAC rs746607921, gnomAD rs746607921, REVEL 0.17, CADD 1.19
- T74I (p.Thr74Ile), TOPMed rs1655917505
- T75K (p.Thr75Lys), TOPMed rs915458369, gnomAD rs915458369, REVEL 0.23, CADD 3.79, Uncertain significance
- T75M (p.Thr75Met), rs915458369, ClinGen CA344008444, NCI-TCGA Cosmic COSV6637, ClinVar RCV001099718, REVEL 0.15, CADD 9.52, Uncertain significance, Factor XIII, b subunit, deficiency of
- C76S (p.Cys76Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T77A (p.Thr77Ala), TOPMed rs546919954, REVEL 0.30, CADD 23.40
- T77S (p.Thr77Ser), TOPMed rs546919954
- T78A (p.Thr78Ala), TOPMed rs1249711828, gnomAD rs1249711828, REVEL 0.06, CADD 0.00
- T78S (p.Thr78Ser), TOPMed rs1249711828, gnomAD rs1249711828, REVEL 0.03, CADD 0.02
- E79K (p.Glu79Lys), Ensembl rs868038631
- G80C (p.Gly80Cys), NCI-TCGA Cosmic COSV1008, REVEL 0.55, CADD 25.70, Variant assessed as somatic; moderate impact.
- G80D (p.Gly80Asp), ExAC rs752162323, gnomAD rs752162323, REVEL 0.52, CADD 25.40
- G80S (p.Gly80Ser), Ensembl rs868671131
- W81C (p.Trp81Cys), TOPMed rs1268732162, gnomAD rs1268732162, REVEL 0.75, CADD 27.60, Uncertain significance, Inborn genetic diseases
- S82A (p.Ser82Ala), ExAC rs764860059, TOPMed rs764860059, gnomAD rs764860059, REVEL 0.18, CADD 21.40
- S82F (p.Ser82Phe), NCI-TCGA Cosmic COSV6637, TOPMed rs1655915024, Variant assessed as somatic; moderate impact.
- P83L (p.Pro83Leu), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- E84A (p.Glu84Ala), TOPMed rs1215630158
- P85S (p.Pro85Ser), TOPMed rs1655914715, REVEL 0.59, CADD 26.20
- R86M (p.Arg86Met), NCI-TCGA Cosmic COSV9905, Variant assessed as somatic; moderate impact.
- R86S (p.Arg86Ser), TOPMed rs956705006, gnomAD rs956705006, REVEL 0.10, CADD 17.10
- F88=, NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; low impact.
- F88L (p.Phe88Leu), gnomAD rs1356843456, REVEL 0.11, CADD 20.00
- K89Q (p.Lys89Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K90T (p.Lys90Thr), TOPMed rs1655879851
- C91F (p.Cys91Phe), ExAC rs753737260, TOPMed rs753737260, gnomAD rs753737260, REVEL 0.87, CADD 25.50
- C91R (p.Cys91Arg), Ensembl rs1655879540
- T92S (p.Thr92Ser), rs1655879228, ClinGen CA344007474, NCI-TCGA Cosmic COSV1008, ClinVar RCV003362240, AlphaMissense 0.07, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- T92A (p.Thr92Ala), rs779600903, []
- K93N (p.Lys93Asn), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- P94H (p.Pro94His), NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- P94L (p.Pro94Leu), NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- P94S (p.Pro94Ser), TOPMed rs906803283, gnomAD rs906803283, REVEL 0.70, CADD 26.10
- P94T (p.Pro94Thr), TOPMed rs906803283, gnomAD rs906803283
- D95H (p.Asp95His), rs1183360497, NCI-TCGA Cosmic COSV6637, gnomAD rs1183360497, REVEL 0.13, CADD 17.90, Variant assessed as somatic; moderate impact.
- D95V (p.Asp95Val), TOPMed rs1655878521
- L96M (p.Leu96Met), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- S97N (p.Ser97Asn), ExAC rs755849086, gnomAD rs755849086
- G99C (p.Gly99Cys), ExAC rs767417732, gnomAD rs767417732, REVEL 0.59, CADD 24.90
- Y100* (p.Tyr100Ter), rs779048554, ClinGen CA1308605, ClinVar RCV000851768, ClinVar RCV002266896, Pathogenic
- Y100C (p.Tyr100Cys), ExAC rs763050735, TOPMed rs763050735, gnomAD rs763050735
- Y100F (p.Tyr100Phe), ExAC rs763050735, TOPMed rs763050735, gnomAD rs763050735
- I101N (p.Ile101Asn), rs753009140, UniProt VAR 074564, ExAC rs753009140, TOPMed rs753009140, REVEL 0.39, CADD 23.10, Likely pathogenic, not provided
- D103N (p.Asp103Asn), Ensembl rs1558312130, REVEL 0.10, CADD 17.30
- V104I (p.Val104Ile), ExAC rs765179050, gnomAD rs765179050, REVEL 0.19, CADD 3.04
- K105N (p.Lys105Asn), Ensembl rs2125073144, REVEL 0.19, CADD 17.70
- L106F (p.Leu106Phe), TOPMed rs903500003, gnomAD rs903500003, REVEL 0.19, CADD 2.66
- L106S (p.Leu106Ser), TOPMed rs1655877201, REVEL 0.20, CADD 14.20
- Y108C (p.Tyr108Cys), rs759690063, ExAC rs759690063, TOPMed rs759690063, gnomAD rs759690063, REVEL 0.60, CADD 24.40, Variant assessed as somatic; moderate impact.
- Y108F (p.Tyr108Phe), ExAC rs759690063, TOPMed rs759690063, gnomAD rs759690063, REVEL 0.22, CADD 19.20
- Q111E (p.Gln111Glu), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; moderate impact.
- E112* (p.Glu112Ter), TOPMed rs1558312099
- E112G (p.Glu112Gly), Ensembl rs1379477611
- E112Q (p.Glu112Gln), TOPMed rs1558312099
- N113D (p.Asn113Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N113S (p.Asn113Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M114I (p.Met114Ile), ExAC rs761321639, TOPMed rs761321639, gnomAD rs761321639, REVEL 0.12, CADD 18.10
- M114K (p.Met114Lys), gnomAD rs1301354226, REVEL 0.38, CADD 23.00
- M114L (p.Met114Leu), ExAC rs771577237, gnomAD rs771577237, REVEL 0.03, CADD 0.01
- R115C (p.Arg115Cys), ExAC rs773706837, gnomAD rs773706837, REVEL 0.33, CADD 21.30
- R115H (p.Arg115His), rs6003, ClinGen CA210740, ClinVar RCV000017984, ClinVar RCV000253350, REVEL 0.04, CADD 0.08, Benign, not specified; not provided; Factor XIII, b subunit, deficiency of
- Y116* (p.Tyr116Ter), gnomAD rs1411171378, CADD 31.00
- G117A (p.Gly117Ala), gnomAD rs1655875490, REVEL 0.05, CADD 9.10
- G117D (p.Gly117Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C118S (p.Cys118Ser), Ensembl rs1048993590, REVEL 0.90, CADD 24.00
- C118Y (p.Cys118Tyr), gnomAD rs1159732571, REVEL 0.84, CADD 23.70
- A119S (p.Ala119Ser), rs778659939, NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6637, ExAC rs778659939, REVEL 0.05, CADD 0.60, Variant assessed as somatic; moderate impact.
- A119T (p.Ala119Thr), rs778659939, NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6637, ExAC rs778659939, REVEL 0.03, CADD 0.65, Variant assessed as somatic; moderate impact.
- A119V (p.Ala119Val), rs767986906, NCI-TCGA Cosmic COSV6637, ExAC rs767986906, gnomAD rs767986906, REVEL 0.05, CADD 17.20, Variant assessed as somatic; moderate impact.
- S120L (p.Ser120Leu), Ensembl rs867927881
- G121E (p.Gly121Glu), Ensembl rs865999502
- G121W (p.Gly121Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y122H (p.Tyr122His), rs1248042126, NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6637, TOPMed rs1248042126, REVEL 0.76, CADD 26.10, Variant assessed as somatic; moderate impact.
- T124A (p.Thr124Ala), ExAC rs779600903, TOPMed rs779600903, gnomAD rs779600903, REVEL 0.28, CADD 23.50
- T124S (p.Thr124Ser), ExAC rs779600903, TOPMed rs779600903, gnomAD rs779600903, REVEL 0.48, CADD 23.20
- G127R (p.Gly127Arg), TOPMed rs1558312007, REVEL 0.44, CADD 25.20
- D129G (p.Asp129Gly), Ensembl rs1655873743
- D129N (p.Asp129Asn), Ensembl rs1655873830, REVEL 0.08, CADD 14.10
- D129Y (p.Asp129Tyr), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- E131K (p.Glu131Lys), Ensembl rs868519305, Uncertain significance, Inborn genetic diseases
- V132A (p.Val132Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V132M (p.Val132Met), gnomAD rs1399927293, REVEL 0.07, CADD 15.90
- Q134K (p.Gln134Lys), TOPMed rs1188592788, gnomAD rs1188592788
- C135R (p.Cys135Arg), 1000Genomes rs199567281, ExAC rs199567281, gnomAD rs199567281, REVEL 0.93, CADD 27.60
- C135S (p.Cys135Ser), NCI-TCGA Cosmic COSV6637, REVEL 0.91, CADD 25.80, Variant assessed as somatic; moderate impact.
- C135Y (p.Cys135Tyr), NCI-TCGA Cosmic COSV6637, Variant assessed as somatic; moderate impact.
- L136F (p.Leu136Phe), rs757094432, NCI-TCGA Cosmic COSV6637, UniProt VAR 074565, REVEL 0.44, CADD 24.00, Uncertain significance, in FA13BD
- L136H (p.Leu136His), NCI-TCGA Cosmic COSV6637, Uncertain significance, in FA13BD
- L136I (p.Leu136Ile), rs757094432, NCI-TCGA Cosmic COSV6637, ExAC rs757094432, REVEL 0.34, CADD 23.70, Uncertain significance, in FA13BD
- D138H (p.Asp138His), ExAC rs765498516, TOPMed rs765498516, gnomAD rs765498516, REVEL 0.18, CADD 19.30
- D138N (p.Asp138Asn), ExAC rs765498516, TOPMed rs765498516, gnomAD rs765498516, REVEL 0.08, CADD 15.20
- G139R (p.Gly139Arg), 1000Genomes rs368129885, ESP rs368129885, ExAC rs368129885, TOPMed rs368129885, REVEL 0.75, CADD 27.00
- W140* (p.Trp140Ter), NCI-TCGA Cosmic COSV1008, CADD 37.00, Variant assessed as somatic; high impact.
- W140S (p.Trp140Ser), NCI-TCGA Cosmic COSV1008, Variant assessed as somatic; moderate impact.
Public F13B analysis runs
- F13B analysis run — F13B (1,110 variants) — completed 2026-08-21